AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
Phase 1
Completed
- Conditions
- Dyslipidemia, Renal Insufficiency
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00585143
- Locations
- 🇺🇸
Site Reference ID/Investigator# 6738, Miami, Florida, United States
🇺🇸Site Reference ID/Investigator# 7723, Minneapolis, Minnesota, United States
🇺🇸Site Reference ID/Investigator# 8280, Richmond, Virginia, United States
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00585000
- Locations
- 🇺🇸
Research Site, Durham, North Carolina, United States
Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy
Terminated
- Conditions
- Preterm BirthBirth DefectsType 2 Diabetes
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT00579150
- Locations
- 🇺🇸
Research Site, Wilmington, North Carolina, United States
An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00577265
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 181
- Registration Number
- NCT00577824
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 201
- Registration Number
- NCT00576316
- Locations
- 🇲🇾
Research Site, Kuala Lumpur, Malaysia
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 891
- Registration Number
- NCT00575588
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
Completed
- Conditions
- HypercholesterolemiaPeripheral Vascular DiseaseCVADiabetesCoronary Heart Disease
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2660
- Registration Number
- NCT00574782
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
Completed
- Conditions
- Primary Hypertension
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1940
- Registration Number
- NCT00573742
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: D9421-C, 9mgDrug: D9421-C, 15mgDrug: Placebo
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00573469
- Locations
- 🇯🇵
Research Site, Toyama, Japan
© Copyright 2025. All Rights Reserved by MedPath